Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Puma Biotechnology, Inc. (NASDAQ:PBYI) for five years would be nursing their metaphorical wounds since the share price dropped 96% in that time. And we doubt long term believers are the only worried holders, since the stock price has declined 68% over the last twelve months. Furthermore, it's down 31% in about a quarter. That's not much fun for holders.<\/p>\n
We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.<\/p>\n
Check out our latest analysis for Puma Biotechnology <\/p>\n
Given that Puma Biotechnology didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.<\/p>\n
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).<\/p>\n
NasdaqGS:PBYI Income Statement, December 6th 2019<\/p>\n
This free interactive report on Puma Biotechnology's balance sheet strength is a great place to start, if you want to investigate the stock further.<\/p>\n
Puma Biotechnology shareholders are down 68% for the year, but the market itself is up 18%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 48% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.<\/p>\n
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.<\/p>\n
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.<\/p>\n
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com<\/a>. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.<\/p>\n We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.<\/p>\n <\/p>\n See more here: Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held Puma Biotechnology, Inc. Continue reading
\nThose Who Purchased Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Have A 96% Loss To Show For It - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"